Symbols

ITCI(Delisted)

Intra-cellular·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ITCI

Intra-Cellular Therapies, Inc.

A biopharmaceutical company that develops therapeutics for central nervous system (CNS) disorders

Industry

Established Date

05/22/2001

Listing Date

01/31/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

860

Fiscal Year Ends

12-31

Website

www.intracellulartherapies.com

Security Type

Common stock

Office address

135 Route 202/206, Suite 6, Bedminster, New Jersey, 07921

Business

Introduction

Intra-cellular Therapies, Inc., was incorporated in Delaware on May 22, 2001 and began operations in June 2002. The company was founded to develop drugs for the treatment of neurological and psychiatric diseases. ITI is a biopharmaceutical company focused on innovating and developing clinical small molecule drugs to improve medical conditions for mental disorders in the central nervous system. The company's leading product, ITI-007, has been clinically developed into a first-class drug for the treatment of schizophrenia. Drugs currently used to treat schizophrenia also do not fully address a range of symptoms of central nervous system disease. These existing drugs are also limited by their powerful side effects. ITI-007 is used to treat many symptoms, including acute and residual schizophrenia, with improved safety and tolerability.

Company Financials

EPS

ITCI has released its 2024 Q4 earnings. EPS was reported at -0.16, versus the expected -0.11, missing expectations. The chart below visualizes how ITCI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ITCI has released its 2024 Q4 earnings report, with revenue of 199.22M, reflecting a YoY change of 50.81%, and net profit of -16.89M, showing a YoY change of 40.92%. The Sankey diagram below clearly presents ITCI's revenue sources and cost distribution.